Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial ...
The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...
Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...
Acurx Pharmaceuticals’ DNA Polymerase IIIC inhibitors receives US patent: Staten Island, New York Wednesday, February 4, 2026, 15:00 Hrs [IST] Acurx Pharmaceuticals, Inc., a lat ...
Every time a cell divides, it must copy its entire genome so that each daughter cell inherits a complete set of DNA. During that process, enzymes known as polymerases race along the DNA to copy its ...
DNA pol IIIC inhibitors have been clinically validated with the first-generation inhibitor ibezapolstat (IBZ), now entering Phase 3 clinical trials for Clostridioides difficile infection. IBZ has ...
Andrés Aguilera's laboratory, in collaboration with that of Ralf Wellinger (both professors in the Department of Genetics at the University of Seville in CABIMER) and with PharmaMAR, has identified ...
STATEN ISLAND, N.Y., Feb. 19, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results